Literature DB >> 22748473

Immunohistochemical panel for distinguishing esophageal adenocarcinoma from squamous cell carcinoma: a combination of p63, cytokeratin 5/6, MUC5AC, and anterior gradient homolog 2 allows optimal subtyping.

Michael A DiMaio1, Shirley Kwok, Kelli D Montgomery, Anson W Lowe, Reetesh K Pai.   

Abstract

Distinguishing adenocarcinoma and squamous cell carcinoma of the esophagus is often based on morphological criteria and can be difficult in small biopsies. We analyzed commonly used immunohistochemical markers (p63, cytokeratin 5/6, cytokeratin 7, CDX2, MUC2, and MUC5AC) and 2 new markers, anterior gradient homolog 2 and SOX2, in esophageal carcinomas to establish the best panel to distinguish these tumors. Tissue microarrays with 69 esophageal adenocarcinomas and 41 whole sections of esophageal squamous cell carcinomas were stained for these markers and semiquantitatively scored. Sensitivities and specificities were calculated for individual markers and select combinations using the morphological diagnosis as a gold standard. All squamous cell carcinomas expressed p63 with 38 of 41 demonstrating reactivity in more than 75% of tumor cells. Cytokeratin 5/6 expression was seen in 40 of 41 squamous cell carcinomas with 39 of 41 demonstrating reactivity in more than 75% of tumor cells. SOX2 expression was present in 35 of 41 of squamous cell carcinomas but also in 24 of 69 of adenocarcinomas, frequently demonstrating extensive reactivity in adenocarcinomas. Anterior gradient homolog 2 was highly sensitive for adenocarcinoma and present in 68 of 69 of cases, but anterior gradient homolog 2 reactivity was also identified in 15 of 41 of squamous cell carcinomas, typically demonstrating focal reactivity in squamous cell carcinoma. MUC5AC expression was seen almost exclusively in adenocarcinomas with only a single squamous cell carcinoma demonstrating focal MUC5AC staining. Overall, the dual expression of both p63 and cytokeratin 5/6 was 99% specific and 98% sensitive for squamous cell carcinoma. In addition, anterior gradient homolog 2 and MUC5AC are useful positive markers of adenocarcinoma in the setting of absent or diminished p63 and cytokeratin 5/6 staining.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22748473      PMCID: PMC3465493          DOI: 10.1016/j.humpath.2012.03.019

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  17 in total

1.  Software tools for high-throughput analysis and archiving of immunohistochemistry staining data obtained with tissue microarrays.

Authors:  Chih Long Liu; Wijan Prapong; Yasodha Natkunam; Ash Alizadeh; Kelli Montgomery; C Blake Gilks; Matt van de Rijn
Journal:  Am J Pathol       Date:  2002-11       Impact factor: 4.307

2.  Anterior gradient 2 overexpression in lung adenocarcinoma.

Authors:  Marco Pizzi; Matteo Fassan; Mariangela Balistreri; Alessandra Galligioni; Federico Rea; Massimo Rugge
Journal:  Appl Immunohistochem Mol Morphol       Date:  2012-01

3.  Expression of p53-related protein p63 in the gastrointestinal tract and in esophageal metaplastic and neoplastic disorders.

Authors:  J N Glickman; A Yang; A Shahsafaei; F McKeon; R D Odze
Journal:  Hum Pathol       Date:  2001-11       Impact factor: 3.466

4.  Cytokeratin phenotyping does not help in distinguishing oesophageal adenocarcinoma from cancer of the gastric cardia.

Authors:  M G F van Lier; F J Bomhof; I Leendertse; M Flens; A T Balk; R J L F Loffeld
Journal:  J Clin Pathol       Date:  2005-07       Impact factor: 3.411

5.  CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: an immunohistochemical survey of 476 primary and metastatic carcinomas.

Authors:  Robert W Werling; Hadi Yaziji; Carlos E Bacchi; Allen M Gown
Journal:  Am J Surg Pathol       Date:  2003-03       Impact factor: 6.394

6.  Immunoreactivity of cytokeratins (CK7, CK20) and mucin peptide core antigens (MUC1, MUC2, MUC5AC) in adenocarcinomas, normal and metaplastic tissues of the distal oesophagus, oesophago-gastric junction and proximal stomach.

Authors:  U Flucke; E Steinborn; V Dries; S P Mönig; P M Schneider; J Thiele; A H Hölscher; H P Dienes; S E Baldus
Journal:  Histopathology       Date:  2003-08       Impact factor: 5.087

7.  Identical cytokeratin expression pattern CK7+/CK20- in esophageal and cardiac cancer: etiopathological and clinical implications.

Authors:  A Driessen; P Nafteux; T Lerut; D Van Raemdonck; P De Leyn; L Filez; F Penninckx; K Geboes; N Ectors
Journal:  Mod Pathol       Date:  2004-01       Impact factor: 7.842

8.  Prognostic relevance of AGR2 expression in breast cancer.

Authors:  Florian Rudolf Fritzsche; Edgar Dahl; Stefan Pahl; Mick Burkhardt; Jun Luo; Empar Mayordomo; Tserenchunt Gansukh; Anja Dankof; Ruth Knuechel; Carsten Denkert; Klaus-Jürgen Winzer; Manfred Dietel; Glen Kristiansen
Journal:  Clin Cancer Res       Date:  2006-03-15       Impact factor: 12.531

9.  Multiple dose-dependent roles for Sox2 in the patterning and differentiation of anterior foregut endoderm.

Authors:  Jianwen Que; Tadashi Okubo; James R Goldenring; Ki-Taek Nam; Reiko Kurotani; Edward E Morrisey; Olena Taranova; Larysa H Pevny; Brigid L M Hogan
Journal:  Development       Date:  2007-05-23       Impact factor: 6.868

10.  Mucin pattern reflects the origin of the adenocarcinoma in Barrett's esophagus: a retrospective clinical and laboratorial study.

Authors:  Sergio Szachnowicz; Ivan Cecconello; Ulysses Ribeiro; Kiyoshi Iriya; Roberto El Ibrahim; Flávio Roberto Takeda; Carlos Eduardo Pereira Corbett; Adriana Vaz Safatle-Ribeiro
Journal:  World J Surg Oncol       Date:  2009-03-09       Impact factor: 2.754

View more
  26 in total

1.  Expression of AGR2 in pituitary adenomas and its association with tumor aggressiveness.

Authors:  Mamatemin Tohti; Junyang Li; Chiyuan Ma; Wanchun Li; Zhenfeng Lu; Yuebing Hu
Journal:  Oncol Lett       Date:  2015-09-21       Impact factor: 2.967

Review 2.  Pathogenesis and Cells of Origin of Barrett's Esophagus.

Authors:  Jianwen Que; Katherine S Garman; Rhonda F Souza; Stuart Jon Spechler
Journal:  Gastroenterology       Date:  2019-05-10       Impact factor: 22.682

Review 3.  Anterior gradient proteins in gastrointestinal cancers: from cell biology to pathophysiology.

Authors:  Céline Posseme; Federico Di Modugno; Emeric Boisteau; Julien Edeline; Cédric Coulouarn; Roman Hrstka; Andrea Martisova; Frédéric Delom; Xavier Treton; Leif A Eriksson; Eric Chevet; Astrid Lièvre; Eric Ogier-Denis
Journal:  Oncogene       Date:  2022-09-06       Impact factor: 8.756

4.  SOX2 as a novel marker to predict neoplastic progression in Barrett's esophagus.

Authors:  Sophie van Olphen; Katharina Biermann; Manon C W Spaander; Florine Kastelein; Ewout W Steyerberg; Hans A Stoop; Marco J Bruno; Leendert H J Looijenga
Journal:  Am J Gastroenterol       Date:  2015-09-01       Impact factor: 10.864

Review 5.  American Registry of Pathology Expert Opinions: Evaluation of poorly differentiated malignant neoplasms on limited samples - Gastrointestinal mucosal biopsies.

Authors:  Andrew M Bellizzi; Elizabeth A Montgomery; Jason L Hornick
Journal:  Ann Diagn Pathol       Date:  2019-11-15       Impact factor: 2.090

Review 6.  Cancer stem cells in human digestive tract malignancies.

Authors:  Fatemeh B Rassouli; Maryam M Matin; Morvarid Saeinasab
Journal:  Tumour Biol       Date:  2015-10-07

7.  Polymorphisms of Genes Related to Function and Metabolism of Vitamin D in Esophageal Adenocarcinoma.

Authors:  Saurabh Singhal; Harit Kapoor; Saravanan Subramanian; Devendra K Agrawal; Sumeet K Mittal
Journal:  J Gastrointest Cancer       Date:  2019-12

8.  A Rare Case of a Primary Squamous Cell Carcinoma of the Stomach Presenting as a Submucosal Mass.

Authors:  Wolf von Waagner; Zhuo Wang; Antonio I Picon
Journal:  Case Rep Surg       Date:  2015-06-21

Review 9.  Systematic review and meta-analysis of immunohistochemical prognostic biomarkers in resected oesophageal adenocarcinoma.

Authors:  L H McCormick Matthews; F Noble; J Tod; E Jaynes; S Harris; J N Primrose; C Ottensmeier; G J Thomas; T J Underwood
Journal:  Br J Cancer       Date:  2015-06-25       Impact factor: 7.640

10.  High expression of AGR2 in lung cancer is predictive of poor survival.

Authors:  Mohammed Alavi; Vei Mah; Erin L Maresh; Lora Bagryanova; Steve Horvath; David Chia; Lee Goodglick; Alvin Y Liu
Journal:  BMC Cancer       Date:  2015-10-06       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.